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Abstract
The cornerstone of pharmacotherapy for OCD is serotonin reuptake inhibition, either with clomipramine or with selective
serotonin reuptake inhibitors (SSRIs). In spite of the success of serotonin reuptake inhibiting drugs, nearly half of OCD
patients do not respond to treatment. Treatment response may be affected by genetic polymorphisms of the P450 metabolic
system. The four most common enzyme-activity reducing polymorphisms of the P450 CYP2D6 enzyme were determined in
91 outpatients with primary OCD according to DSM-IV criteria, receiving dosages titrated upward to 300 mg/day of
venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule. Our results show that the investigated CYP2D6
polymorphisms are not a decisive factor in the response to paroxetine and venlafaxine treatment in OCD in spite of their
highly significant effect on the blood levels of these medicines.
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Introduction
Serotonin reuptake inhibitors (SRIs) are the most
effective pharmacological treatment currently avail-
able for patients with obsessive-compulsive disorder
(OCD). Still, up to 4060% of OCD patients do not
respond to SRI treatment [1]. We recently reported
the pharmacogenetic effect of the 44-bp insertion/
deletion 5-HTTLPR polymorphism and the 5-
HT2A 1438G/A polymorphism in serotonin-related
genes on the efficacy of venlafaxine and paroxetine
treatment of OCD [2]. Our findings suggest that
these polymorphisms influence the pharmacody-
namics of venlafaxine and paroxetine. Polymorph-
isms in the P450 CYP2D6 enzyme are known to
change the pharmacokinetics of venlafaxine and
paroxetine [3]. In an effort to characterize whether
this pharmacokinetic factor influences the response
to paroxetine or venlafaxine treatment, we deter-
mined four common polymorphisms of the P450
CYP2D6 enzyme in 91 OCD patients. We investi-
gated the effect of the studied polymorphisms on the
blood levels of paroxetine and (O-desmethyl)venla-
faxine and on the response to paroxetine treatment
or venlafaxine treatment.
Methods
Ninety-one outpatients gave written informed
consent for participation in this study, which had
been approved by the University of Utrecht Medical
Ethical Review committee (Utrecht, The Nether-
lands). The studied population is described in detail
by Denys et al. [2]. Severity of obsessive-compulsive
symptoms was rated with the YaleBrown Obsessive
Compulsive Scale (YBOCS), depressive symptoms
with the Hamilton Rating scale for Depression
(HAM-D) and anxiety with the Hamilton Rating
Scale for Anxiety (HAM-A). Only patients with a
score of at least 18 on the YBOCS, or at least 12 if
only obsessions or only compulsions were present,
were included. Patients with a major depressive
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on the 17-item HAM-D on admission were excluded.
Other exclusion criteria were diagnoses of major
depression, bipolar disorder, schizophrenia, other
psychotic conditions, substance related disorder
within the last 6 months, primary anxiety disorders,
personality disorders, use of a concomitant psycho-
tropic drug, organic mental disorders, epilepsy and
any structural central nervous system disorder.
Furthermore, clinically significant cardiovascular,
gastrointestinal, pulmonary, renal, hepatic, endo-
crine or hematological conditions resulted in exclu-
sion from this study. Of these 91 patients, 17 dropped
out of this study because of lack of motivation,
uncertain medication use or failure to collect blood
for determination of drug plasma concentrations.
The 74 remaining patients have following character-
istics: 39.2% male; positive family history, 36.1%;
age at onset, 19.599.0; age at admission to study,
36.3911.6; baseline YBOCS score, 25.095.7.
The patients were randomly assigned in a 12-week,
double-blind trial to receive dosages titrated upward
to 300 mg/day of venlafaxine or 60 mg/day of parox-
etine, using a fixed dosing schedule. (see Denys et al.
[4] for details on the dosing schedule). The patients
received no additional drugs affecting the P450
enzyme system and were treatment free at baseline
for at least 1 month. Primary efficacy was assessed by
thechangefrombaselineontheYBOCS,andresponse
was defined as a ]25% reduction on the YBOCS.
Blood samples were collected from each subject
and frozen at 808C. Blood levels of paroxetine,
venlafaxine and O-desmethylvenlafaxine were deter-
mined at weeks 0, 1, 3, 5, 8, 10 and 12 by high-
performanceliquidchromatographywithfluorescence
detection [5]. Blood for the drug level determinations
was collected at the response assessment in those
weeks, at a random time point after ingestion of the
medicine.
DNA was extracted from 10 ml of peripheral blood
according to standard procedures. The samples were
genotyped using TaqMan† Drug Metabolism Gen-
otyping Assays from Applied Biosystems for the
NCBI dbSNP identification numbers rs3892097
(1846G A polymorphism, resulting in the inactive
CYP2D6 allele 4 [6]), rs5030655 (1707T Del
polymorphism, resulting in the inactive CYP2D6
allele 6 [6]), rs1065852 (100C T polymorphism,
resulting in the reduced activity CYP2D6 allele 10
when not in combination with the 1846G A
polymorphism [7]) and rs28371725 (2988G A
polymorphism, resulting in the reduced activity
CYP2D6 allele 41 [8]. In a Caucasian population,
the frequency of all inactive and all reduced activity
alleles is about 35%, of which 8090% are caused by
the four analyzed SNPs [9,10].
Results
The measured minor allele frequencies for
rs3892097, rs5030655, rs1065852, and rs28371725
are 0.24, 0.02, 0.26 and 0.08, respectively. This is in
accordance with the minor allele frequencies reported
by Applied Biosystems: 0.20, 0.00, 0.21 and 0.11,
respectively. Fifty-seven percent of the patients have
at least one reduced activity CYP2D6 allele while
13% have two reduced activity CYP2D6 alleles.
To assess the effect of the polymorphisms on the
medication plasma levels, all 6 measurements were
averaged and two-tailed T-test statistics was per-
formed on this average (see Table I). Paroxetine-
treated patients with at least one reduced activity
CYP2D6 allele show significantly higher paroxetine
levels (P0.037) compared to patients with normal
alleles. Venlafaxine-treated patients with at least one
reduced activity CYP2D6 allele show significantly
higher venlafaxine levels (P0.018) compared to
patients with normal alleles. When considering the
venlafaxine metabolites, insignificant differences are
found with lower O-desmethylvenlafaxine levels
(P0.397) and higher combined venlafaxine
O-desmethylvenlafaxine levels (P0.065) compared
to patients with normal alleles.
In patients with two reduced activity CYP2D6
alleles, the same results are found but with a higher
statistical significance level. The plasma metabo-
lite levels also differ significantly. Patients with
two reduced activity CYP2D6 alleles show higher
Table I. Plasma levels and response in patients with at least one reduced activity CYP2D6 allele (poor metabolizers) versus patients with
only normal alleles.
Plasma levels (ng/ml)
Response (YBOCS
decrease  25%)
Response (YBOCS
decrease  35%)
Paroxetine treated patients (N35)
Poor metabolizer (N17) 177982
Two-tailed t-test P0.037
75%
x2-test df1 P1.00
55%
x2-test df1 P1.00
Normal metabolizer (N18) 125961 80% 50%
Venlafaxine treated patients (N39)
Poor metabolizer (N22) 3909387
Two-tailed t-test P0.018
52%
x2-test df1 P0.77
44%
x2-test df1 P0.76
Normal metabolizer (N17) 1519113 58% 53%
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levels (PB0.0005), lower O-desmethylvenlafaxine
levels (P0.017) and higher combined
venlafaxineO-desmethylvenlafaxine levels (P
0.007) compared to patients with normal alleles.
In contrast with these findings, the allele frequen-
cies of the individual polymorphisms are almost
identical (data not shown) in the responders and
non-responders both for the paroxetine group and
the venlafaxine group. Pearson chi-square statistics
show no significant differences when comparing
venlafaxine and paroxetine response in patients
with at least one reduced activity CYP2D6 allele
versus patients with normal alleles (see Table I).
Additionally, no significant differences could be
found comparing response in patients with two
reduced activity CYP2D6 alleles versus patients
with normal alleles. In the studied population, these
Pearson chi-square tests have a post-hoc power to
detect an effect size w0.5 of 0.84.
Discussion
This is the first study assessing the direct impact of
CYP2D6 polymorphisms on pharmacological treat-
ment outcome in OCD. Because CYP2D6 duplica-
tions (resulting in ultra-rapid metabolizers) and the
non-tested CYP2D6 polymorphisms are too un-
common to be studied in a population of 91 patients,
these polymorphisms were not analyzed. Because
patient subgroups based on individual genotypes are
too small to perform useful statistical tests in the
studied population, the patients were divided in
groups with no, at least one or at least two reduced
activity alleles.
From the results, we conclude that the investigated
CYP2D6 polymorphisms are not a decisive factor in
the response to paroxetine and venlafaxine treatment
in OCD in spite of their highly significant effect on
the blood levels of these medicines. Because of a
previously reported lack of effect of paroxetine and
venlafaxine blood levels on YBOCS response [4], it is
expected that the CYP2D6 polymorphisms do not
have a major influence on the response. This lack of
relationship drug plasma levels and YBOCS response
has also been reported for clomipramine, fluoxetine,
fluvoxamine and sertraline [11]. On the other hand, a
few studies report on a doseresponse relationship: A
larger study observed higher venlafaxine blood levels
in responders compared to non-responders, but
found no evidence for a relationship between treat-
ment outcome and blood levels of paroxetine [12].
Hollander et al reported that paroxetine doses of 40
and 60 mg/day (but not 20 mg/day) are effective in
treating acute obsessive-compulsive disorder [13].
Yaryura-Tobias et al indicate that doses of venlafaxine
less than 225 mg/day are not effective in OCD [14].
Doseresponse studies of paroxetine and/or venlafax-
ine in OCD treatment are scarce. The results in this
study show additional evidence that blood concentra-
tions are not a major factor in the response to
venlafaxine and paroxetine treatment of OCD.
Given the fact that venlafaxine and paroxetine are
metabolized primarily by the CYP2D6 enzymes given
the fact that the most common reduced activity alleles
do not have a major effect on response and given the
fact that other CYP2D6 polymorphisms are rare,
previous and future studies on response to venlafaxine
and paroxetine treatment in OCD are unlikely to be
confounded by CYP2D6 polymorphisms.
Key points
. The four most common enzyme-activity redu-
cing polymorphisms of the P450 CYP2D6
enzyme were determined in 91 outpatients
with primary OCD.
. Patients received dosages titrated upward to
300 mg/day of venlafaxine or 60 mg/day of
paroxetine, using a fixed dosing schedule.
. The investigated CYP2D6 polymorphisms are
not a decisive factor in the response to treat-
ment in spite of their highly significant effect on
the blood levels of these medicines.
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